Department of Gastroenterological Surgery and Clinical Oncology, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.
Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba, 260-8670, Japan.
Esophagus. 2022 Oct;19(4):617-625. doi: 10.1007/s10388-022-00939-0. Epub 2022 Jul 3.
Cofilin (CFL1, actin-binding protein) and β-actin (ACTB) are key molecules in the polymerization and depolymerization of actin microfilaments. The levels of these antibodies were analyzed, and the clinicopathological significance in patients with esophageal carcinoma were evaluated.
The levels of anti-CFL1 and anti-ACTB antibodies were analyzed in serum samples of patients with esophageal carcinoma and of healthy donors. Eighty-seven cases underwent radical surgery and the clinicopathological characteristics and prognosis was examined.
Serum anti-CFL1 antibody (s-CFL1-Ab) levels and anti-ACTB antibody (s-ACTB-Ab) levels were significantly higher in patients with esophageal carcinoma than in healthy donors. Following the receiver operating characteristic curve analysis between healthy donors and esophageal carcinoma, the sensitivity and specificity for serum anti-CFL1 antibody (s-CFL1-Ab) were 53.3% and 68.8%. The sensitivity and specificity for serum anti-ACTB antibody (s-ACTB-Ab) were 54.9% and 67.7%, respectively. Univariate and multivariate analysis showed that s-CFL1-Ab and s-ACTB-Ab levels were not associated with sex, age, tumor depth, lymph node metastasis, or anti-p53-antibody levels. s-ACTB-Ab levels but not s-CFL1-Ab levels significantly correlated with squamous cell carcinoma antigen. Neither s-CFL1-Ab nor s-ACTB-Ab levels alone were obviously related to overall survival. However, patients with low s-CFL1-Ab levels and high s-ACTB-Ab levels exhibited significantly more unfavorable prognoses than those with high s-CFL1-Ab and low s-ACTB-Ab levels.
Serum levels of anti-CFL1 and anti-ACTB antibodies were significantly higher in patients with esophageal carcinoma than in healthy donors. A combination of low anti-CFL1 and high anti-ACTB antibodies is a poor prognostic factor in esophageal carcinoma.
丝切蛋白（CFL1，肌动蛋白结合蛋白）和β-肌动蛋白（ACTB）是肌动蛋白微丝聚合和解聚的关键分子。分析了这些抗体的水平，并评估了其在食管癌患者中的临床病理意义。
分析了食管癌患者和健康供体血清样本中的抗 CFL1 和抗 ACTB 抗体水平。对 87 例患者进行根治性手术，并检查了其临床病理特征和预后。
食管癌患者血清抗丝切蛋白 1 抗体（s-CFL1-Ab）和抗β-肌动蛋白抗体（s-ACTB-Ab）水平明显高于健康供体。在健康供体和食管癌患者之间的受试者工作特征曲线分析中，血清抗丝切蛋白 1 抗体（s-CFL1-Ab）的敏感性和特异性分别为 53.3%和 68.8%。血清抗β-肌动蛋白抗体（s-ACTB-Ab）的敏感性和特异性分别为 54.9%和 67.7%。单因素和多因素分析表明，s-CFL1-Ab 和 s-ACTB-Ab 水平与性别、年龄、肿瘤深度、淋巴结转移或抗 p53 抗体水平无关。s-ACTB-Ab 水平而非 s-CFL1-Ab 水平与鳞状细胞癌抗原显著相关。s-CFL1-Ab 和 s-ACTB-Ab 水平均与总生存期无关。然而，s-CFL1-Ab 水平低且 s-ACTB-Ab 水平高的患者预后明显比 s-CFL1-Ab 水平高且 s-ACTB-Ab 水平低的患者更差。
食管癌患者血清中抗 CFL1 和抗 ACTB 抗体水平明显高于健康供体。低抗 CFL1 与高抗 ACTB 抗体的组合是食管癌的不良预后因素。
